OneSource Specialty Pharma Limited (ONESOURCE) AI Stock Analysis

0 Followers

OneSource Specialty Pharma Limited

(NSE:ONESOURCE)

Select Model

Rating:48Neutral

Price Target:INR 1,575.00▼(-0.44% Downside)

Action:reiterated

Date:10/28/26

The score is primarily constrained by deteriorating profitability and severe cash-flow weakness. Positive revenue growth, balance-sheet support, and a price above its moving averages provide partial offset, while the negative P/E and absence of dividend support weigh on valuation.

Positive Factors

FY2026 Revenue AccelerationRevenue growth of about 77% in FY2026 indicates strong top-line acceleration after a flat FY2025. If sustained, this momentum can broaden the operating base and provide greater scale for future investment, even though current profitability remains weak.

Negative Factors

Severe Profitability DeteriorationFY2026 net income moved from near breakeven to a large loss, while EBIT dropped sharply year over year. This shows current growth is not converting into earnings and leaves the business more exposed if elevated costs or margin pressure persist.

OneSource Specialty Pharma Limited (ONESOURCE) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 183.67B
Dividend Yield: ―
Average Volume (3M): 48.39K
Price to Earnings (P/E): -10544.7
Beta (1Y): 0.43
Revenue Growth: 10.66%
EPS Growth: -104.59%
Country: India
Employees: 1,674
Sector: General
Sector Strength: 55
Industry: Biotechnology

OneSource Specialty Pharma Limited Business Overview & Revenue Model

Company Description

OneSource Specialty Pharma Limited is a biopharmaceutical company focused on the discovery, advancement, production, and market introduction of biological drug products, primarily offered in diverse injectable formulations. The company conducts its o...

How the Company Makes Money

null

OneSource Specialty Pharma Limited Financial Statement Overview

Summary

Strong revenue growth and a solid equity base are offset by sharply deteriorating profitability and deeply negative operating and free cash flow. Debt has increased, although leverage remains manageable.

Income Statement

42Neutral

Balance Sheet

63Positive

Cash Flow

35Negative

Financial statement breakdown
Breakdown	TTM	Mar 2025	Mar 2025	Mar 2024	Mar 2023
Income Statement
Total Revenue	15.22B	14.45B	14.22B	1.72B	387.14M
Gross Profit	9.83B	10.10B	4.56B	1.01B	183.03M
EBITDA	4.31B	3.61B	3.04B	-1.85B	-2.61B
Net Income	399.52M	-2.10M	-738.03M	-3.91B	-8.00B
Balance Sheet
Total Assets	80.13B	75.50B	82.10B	13.09B	20.09B
Cash, Cash Equivalents and Short-Term Investments	1.80B	2.11B	1.03B	222.64M	94.74M
Total Debt	12.95B	9.42B	15.04B	5.71B	8.64B
Total Liabilities	21.09B	16.70B	23.79B	9.13B	12.23B
Stockholders Equity	59.04B	58.81B	58.31B	3.96B	7.85B
Cash Flow
Free Cash Flow	-3.69B	-1.96B	-6.80B	-1.71B	-2.07B
Operating Cash Flow	-399.21M	-678.54M	-1.11B	-1.07B	-1.63B
Investing Cash Flow	-2.51B	-2.01B	-4.95B	5.11B	-678.34M
Financing Cash Flow	2.31B	4.12B	4.79B	-3.91B	1.18B

OneSource Specialty Pharma Limited Technical Analysis

Technical Analysis SentimentPositive

Last Price1582.00

Price Trends

50DMA1529.96Positive

100DMA1568.42Positive

200DMA1548.40Positive

Market Momentum

MACD25.62Negative

RSI57.39Neutral

STOCH65.36Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ONESOURCE, the sentiment is Positive. The current price of 1582.00 is above the 20-day moving average (MA) of 1498.64, above the 50-day MA of 1529.96, and above the 200-day MA of 1548.40, indicating a bullish trend. The MACD of 25.62 indicates Negative momentum. The RSI at 57.39 is Neutral, neither overbought nor oversold. The STOCH value of 65.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ONESOURCE.

OneSource Specialty Pharma Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:ONESOURCE against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:BLUEJET	71Outperform	INR 102.92B	33.48	―	0.22%	-7.05%	-21.25%
IN:CONCORDBIO	65Neutral	INR 124.88B	44.29	―	1.26%	4.02%	-12.81%
IN:SYNGENE	59Neutral	INR 176.38B	95.65	―	0.28%	-5.99%	-60.30%
IN:DCAL	57Neutral	INR 26.25B	40.23	―	―	-20.86%	-34.51%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:ONESOURCE	48Neutral	INR 185.52B	-10544.67	―	―	10.66%	-104.59%
IN:BIOCON	47Neutral	INR 599.15B	123.09	―	0.14%	5.70%	-24.72%

* General Sector Average

Performance Comparison

IN:ONESOURCE and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:ONESOURCE	OneSource Specialty Pharma Limited	1582.00	-146.75	-8.49%
IN:BIOCON	Biocon Limited	367.90	-48.65	-11.68%
IN:BLUEJET	Blue Jet Healthcare Limited	536.10	-43.49	-7.50%
IN:CONCORDBIO	Concord Biotech Ltd.	597.65	-125.27	-17.33%
IN:DCAL	Dishman Carbogen Amcis Ltd.	175.00	-71.50	-29.01%
IN:SYNGENE	Syngene International Ltd.	442.80	-217.13	-32.90%

OneSource Specialty Pharma Limited Corporate Events

OneSource Specialty Pharma Sets Q2 FY27 Earnings Call for October 27

Oct 21, 2026

OneSource Specialty Pharma Limited has scheduled an earnings call with analysts and investors on October 27, 2026, at 18:30 IST to discuss its unaudited financial results for the quarter ended September 30, 2026. The call will be led by CEO & MD Neer...

OneSource Specialty Pharma modestly boosts capital through ESOP share allotment

Sep 25, 2026

OneSource Specialty Pharma Limited has approved the allotment of 900 equity shares under its Employee Stock Option Plan 2021 to an eligible employee, following the exercise of vested options. The new shares, issued at a premium to their INR 1 par val...

OneSource Specialty Pharma underscores governance focus at 19th AGM held virtually

Sep 23, 2026

OneSource Specialty Pharma Limited held its 19th Annual General Meeting, and second since listing, on September 23, 2026 via video conference, in line with regulatory guidelines under the Companies Act and SEBI listing norms. The meeting introduced s...

OneSource Specialty Pharma appoints B S R & Co LLP as new statutory auditor

Sep 23, 2026

OneSource Specialty Pharma Limited has appointed M/s B S R & Co LLP as its new statutory auditor, following shareholder approval at the company’s 19th Annual General Meeting held on September 23, 2026. The audit firm will serve a five-year term, exte...

OneSource Specialty Pharma Sets Date for 19th AGM and Releases FY 2025-26 Annual Report

Aug 31, 2026

OneSource Specialty Pharma Limited has scheduled its 19th Annual General Meeting, the second since listing, to be held on September 23, 2026, at 17:00 IST via video conferencing and other audiovisual means. The company has released its notice of AGM,...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 28, 2026

OneSource Specialty Pharma Limited AI Stock Analysis